ERBB2 and neoplasm: Of several molecular markers reportedly predicting unfavorable tumor response to CRT or radiotherapy [8], [13], [14], [15], [16], [17], [18], [19], [20], those that can be targeted by small molecules or monoclonal antibodies include erythroblastic leukemia viral oncogene homolog 2 (erbB2, also known as HER2/neu) [8], nuclear factor-κB (NFκB) [13], [14], mutant p53 [17], [18], and survivin [19].